Soluble Guanylate Cyclase Stimulators (Riociguat) in Pulmonary Hypertension: Data from Real-Life Clinical Practice in a 3-Year Follow-Up.

Fernanda Brum Spilimbergo Taís Silveira AssmannMarcelo BellonLaís Machado HoscheidtCássia Ferreira Braz CaurioMárcia PuchalskiBruno HochheggerGabriela Roncato Gisela Martina Bohns Meyer

Published in: Arquivos brasileiros de cardiologia (2022)

In our real-life cohort, most patients with PH treated with riociguat showed stable or improved risk parameters, especially in the 6MWT, at 3 years of follow-up.

Keyphrases

pulmonary hypertension
clinical practice
pulmonary artery
pulmonary arterial hypertension
electronic health record
big data
machine learning
coronary artery
data analysis